National Bank of Canada FI Purchases 141,221 Shares of Becton, Dickinson and Company (NYSE:BDX)

National Bank of Canada FI lifted its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 83.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 309,963 shares of the medical instruments supplier's stock after acquiring an additional 141,221 shares during the quarter. National Bank of Canada FI owned approximately 0.11% of Becton, Dickinson and Company worth $76,006,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Jeppson Wealth Management LLC raised its stake in shares of Becton, Dickinson and Company by 4.0% during the third quarter. Jeppson Wealth Management LLC now owns 1,028 shares of the medical instruments supplier's stock worth $266,000 after buying an additional 40 shares during the last quarter. Value Partners Investments Inc. boosted its position in shares of Becton, Dickinson and Company by 5.2% in the 3rd quarter. Value Partners Investments Inc. now owns 867 shares of the medical instruments supplier's stock worth $225,000 after purchasing an additional 43 shares during the last quarter. Dover Advisors LLC increased its holdings in Becton, Dickinson and Company by 1.7% in the third quarter. Dover Advisors LLC now owns 2,702 shares of the medical instruments supplier's stock valued at $699,000 after purchasing an additional 45 shares during the last quarter. Mendel Money Management lifted its stake in Becton, Dickinson and Company by 3.0% in the third quarter. Mendel Money Management now owns 1,536 shares of the medical instruments supplier's stock valued at $397,000 after buying an additional 45 shares during the period. Finally, Phillips Wealth Planners LLC grew its position in shares of Becton, Dickinson and Company by 6.0% during the 3rd quarter. Phillips Wealth Planners LLC now owns 818 shares of the medical instruments supplier's stock worth $211,000 after buying an additional 46 shares during the period. 86.97% of the stock is currently owned by institutional investors.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,715 shares of the firm's stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total value of $399,269.15. Following the completion of the transaction, the executive vice president now directly owns 5,381 shares of the company's stock, valued at $1,252,750.61. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, EVP Michael David Garrison sold 1,715 shares of the stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total value of $399,269.15. Following the sale, the executive vice president now owns 5,381 shares in the company, valued at approximately $1,252,750.61. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Thomas J. Spoerel sold 282 shares of Becton, Dickinson and Company stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the transaction, the senior vice president now directly owns 2,276 shares of the company's stock, valued at $542,348.04. The disclosure for this sale can be found here. 0.31% of the stock is owned by company insiders.

Becton, Dickinson and Company Stock Down 2.4 %

NYSE BDX traded down $5.67 on Friday, reaching $234.68. The company had a trading volume of 1,722,353 shares, compared to its average volume of 1,291,373. The company's fifty day moving average is $238.45 and its 200-day moving average is $240.27. The firm has a market capitalization of $67.80 billion, a price-to-earnings ratio of 51.69, a price-to-earnings-growth ratio of 1.93 and a beta of 0.45. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.64 and a current ratio of 1.41. Becton, Dickinson and Company has a 1-year low of $229.40 and a 1-year high of $287.32.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.97 by $0.20. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The business had revenue of $5.05 billion for the quarter, compared to analyst estimates of $5.04 billion. During the same quarter last year, the firm earned $2.86 EPS. Becton, Dickinson and Company's revenue for the quarter was up 4.6% compared to the same quarter last year. On average, research analysts forecast that Becton, Dickinson and Company will post 13.04 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Monday, June 10th will be issued a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 1.62%. The ex-dividend date of this dividend is Monday, June 10th. Becton, Dickinson and Company's payout ratio is 83.70%.

Wall Street Analysts Forecast Growth

Separately, Barclays boosted their price objective on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an "overweight" rating in a report on Monday, February 5th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $280.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.